Pennsylvania Dutch community builds its own gene therapy programme after biopharma passes on rare disease
A STAT News report describes how an Amish and Mennonite community in Pennsylvania Dutch country has established its own drug development effort to tackle a rare inherited disease that larger pharmaceutical companies declined to pursue.
A report by STAT News describes an unusual community-led drug development initiative in Pennsylvania Dutch country, where an Amish and Mennonite community has established its own organisation to develop a gene therapy for a rare inherited disease disproportionately affecting its members. The community, which has long faced a higher burden of certain recessive genetic conditions because of founder effects and historical population bottlenecks, had been unable to attract sustained biopharma investment for the condition in question.
The initiative — which the report describes as pairing community resources, local clinical knowledge, and academic partnerships — represents a model of patient-community-driven rare disease research that sits outside the conventional pharmaceutical development pathway. Founder effects, in which a small founding population transmits rare recessive variants at elevated frequency to a large descendant population, are well characterised in Anabaptist communities and have historically posed challenges for matching patients to clinical trial recruitment.
The story is of interest to researchers working in rare disease, genetic counsellors involved in community genetics, and educators teaching about population genetics, health equity, and the challenges of orphan disease drug development. It also illustrates how founder population genetics intersects with real-world access to therapeutic research. The underlying article is behind a STAT+ paywall; this summary is based on the publicly available lede and contextual knowledge.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Some inherited diseases are so rare that large pharmaceutical companies do not develop treatments for them. A community of Amish and Mennonite families in the United States has responded by setting up its own effort to develop a gene therapy — a type of treatment that aims to correct or compensate for a faulty gene. The community has a higher rate of certain inherited conditions because it descends from a relatively small number of founders, a well-understood pattern in genetics. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-10-27STAT+: Pennsylvania Dutch country, tired of waiting for biopharma, builds drug company of its own